drugset / Trial / NCT03077451
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Phase 2
Completed
36 enrolled
AIDS Malignancy Consortium
AIDS and Cancer Specimen Resource · collabMontefiore Medical Center · collabNational Cancer Institute (NCI) · collabThe Emmes Company, LLC · collabUniversity of Arkansas · collabUniversity of California, Los Angeles · collab
NaSingle-groupOpen-labelTreatment
Summary
This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2017-03-13
- Primary completion
- 2022-05-23
- Completion
- 2023-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelfinavir | Other / unclassified | — | Oral |